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1. INTRODUCTION AND PURPOSE 
 
This document details the rules proposed and the presentation that will be followed, as closely as possible, 
when analysing and reporting the main results from TRIUMPH. 
 
 
The purpose of the plan is to: 
1. Ensure that the analysis is appropriate for the aims of the trial, reflects good statistical practice, and 
that interpretation of a priori and post hoc analyses is appropriate. 
2. Explain in detail how the data will be handled and analysed to enable others to perform the actual 
analysis in the event of sickness or other absence. 
 
 
Additional exploratory or auxiliary analyses of data not specified in the protocol are permitted but fall outside 
the scope of this analysis plan (although such analyses would be expected to follow Good Statistical Practice). 
 
 
The analysis strategy will be made available if required by journal editors or referees when the main papers 
are submitted for publication. Additional analyses suggested by reviewers or editors will, if considered 
appropriate, be performed in accordance with this analysis plan, but if reported the source of the request of 
the post-hoc analysis will be declared. 
 
 
Amendments to the statistical analysis plan will be described and justified in the final report of the trial. 
 
 
2. SYNOPSIS OF STUDY DESIGN AND PROCEDURES 
 
Lower Urinary Tract Symptoms (LUTS) refer to issues of difficulty with either storing or passing urine. Problems 
with storing urine (“storage LUTS”) include increased urinary frequency, urgency and having to pass urine 
overnight (nocturia). Urinary urgency can be sufficiently severe to cause urinary incontinence. Problems with 
passing urine may occur while actually urinating (“voiding LUTS”), such as slow stream, or immediately 
afterwards (“post voiding LUTS”), such as dribbling. LUTS are common and bothersome, and affect the lives 




Four LUTS are particularly bothersome: 1) urgency- sudden need to pass urine for fear of leakage; 2) increased 
urinary frequency; 3) nocturia- getting up at night to pass urine; 4) post urination dribbling- leakage just after 
finished passing urine. The impact of these may be exacerbated by concern the individual has that they might 
have a serious illness. 
 
 
In primary care, general practitioners (GPs) principally assess men presenting with LUTS to exclude serious 
conditions, and often treat LUTS in general with a drug aimed at the prostate. However, the wide range of 
potential contributory factors may not be considered. For example, urgency and increased urinary frequency 
may mainly be caused by the bladder rather than the prostate. They may also be caused by the patients’ own 
habits, such as the amount and timing of their caffeine intake. Furthermore, post urination dribbling does not 
respond to drug treatment, and instead needs advice on the need for gentle pressure applied in the right place 
to help expel the few drops of trapped urine. Detecting these factors and giving the patient relevant advice is 
time-consuming and often not offered in primary care. Consequently, men may not receive effective 
treatment, or may be referred to hospital services, leading to extra healthcare costs and potentially major 
interventions. 
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2.1 Trial objectives and aims 
 
2.1.1 Primary objective 
To determine whether manualised and standardised care (intervention) achieves superior symptomatic 
outcome versus usual care for LUTS, measured by the overall International Prostate Symptom Score (IPSS), at 
12 months after consent. 
 
2.1.2 Secondary objectives 
To determine: 
• Whether manualised and standardised care intervention achieves superior disease-specific quality of 
life outcome for LUTS measured by the IPSS Quality of Life score at 6 and 12 months after consent 
• Whether manualised and standardised care intervention achieves superior symptomatic outcome 
for LUTS. This will be measured separately by the overall IPSS score at 6 months after consent and 
International Consultation on Incontinence Questionnaire – Urinary Incontinence Short Form (ICIQ- 
UI-SF) at 6 and 12 months after consent 
• The relative harms of the two pathways 
• The differential effects on other outcomes, such as overall quality of life and general health 
• The acceptability of assessment and provision of care 
• Change in patient perception of their LUTS condition in the two management pathways 
• The cost effectiveness of LUTS management pathways, measured using quality-adjusted life-years 
(QALYs) and the primary outcome at 12 months after consent (to be studied in a health economics 
analysis described in a separate Health Economics Analysis Plan (HEAP)) 
• The differential use of National Health Service (NHS) resources (to be studied in a health economics 
analysis described in a separate HEAP) 
 
 
2.2 Trial design and configuration 
TRIUMPH is a two-arm cluster superiority trial randomising GP practices (1:1) to treat men with a diagnosis of 
LUTS between a care pathway based on manualised and standardised care using active management (non- 
pharmacological “Intervention arm”) and one based on current management (usual care “Comparator arm”). 
The trial design also included an internal pilot recruitment phase of four months’ duration, primarily to verify 
that recruitment was possible before progression to the main phase of the trial. Progression to the full trial 




2.3 Trial centres 
TRIUMPH has two centres: (i) Bristol and (ii) Southampton. 
 
 
2.4 Eligibility criteria 
 
2.4.1 GP practice selection criteria 
GP practices are eligible for the study if a standardised pre-randomisation database search identifies an 
adequate number of eligible patients. Practices must be able to provide adequate treatment room space and 




2.4.2 Participant inclusion criteria 
Adult men (≥ 18 years) with bothersome LUTS. 
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2.4.3 Participant exclusion criteria 
Men are excluded if they: 
• Lack capacity to consent; 
• Are unable to pass urine without a catheter (indwelling or intermittent catheterisation); 
• Have a relevant neurological disease or referral; 
• Are undergoing urological testing for LUTS; 
• Are currently being treated for prostate or bladder cancer; 
• Have previously had prostate surgery; 
• Have poorly controlled diabetes mellitus as determined by the patient’s GP through screening; 
• Have visible haematuria; 
• Are unable to complete assessments in English 
 
 
2.5 Description of intervention 
The intervention arm offers manualised and standardised active management according to the symptomatic 
presentation of the individual patient. The central aspects of the intervention are: 
1. The personal delivery by a nurse/HCA (from either the practice or research team) to educate, emphasise 
positive aspects, and direct the patient to the relevant steps to take personally. 
2. The illustrated booklet of written information “Helping you to take control of your waterworks”. The 
sections included are: 
• Advice on drinks and liquid intake; 
• Advice on controlling an urgent need to pee (urinate); 
• Exercising the muscles between the legs (pelvic floor) to help stop bladder leakage; 
• Advice on emptying the bladder as completely as possible; 
• Advice on getting rid of the last drops; 
• Reducing sleep disturbance caused by needing to pee. 
3. To encourage and gauge adherence to the intervention, we will use regular contacts (initial face-to-face 
appointment, phone call after one week and further contacts 4 and 12 weeks later by phone or email 
according to patient preference). Subsequent routine health care professional (HCP) contact is not planned. 
 
 
The sections of the booklet are tabbed to allow manualised tailoring by the HCP with discrete stickers. The 
booklet is water-resistant and able to lie flat when open. 
 
 
The research/practice nurse/HCA will be provided with a decision tool to assist them in tailoring the treatment 
for each patient at the baseline visit. 
 
 
2.6 Description of the comparator arm 
Usual care (the comparator arm for TRIUMPH) in this study requests sites to continue to follow their standard 
local practice for trial patients allocated to the comparator arm. The qualitative aspect of this trial is exploring 
what usual care looks like for a sample of comparator and intervention practices. 
 
 
2.7 Recruitment, screening and consent 
If practices have sufficient numbers of eligible patients, practices are then eligible for randomisation to either 
the Usual care or Intervention arm. All eligible men with LUTS are identified from the GP site’s clinical database 
using the database search protocol. The list of potential patients is screened for eligibility by the GPs . Once 
screening is complete, the list of eligible patients are uploaded to Docmail for mailout and the trial team 
confirms that this has been done correctly and it is at this point that practices are informed of their 
randomisation (see below for details). 
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Patients are invited to return an expression of interest (EOI) form to indicate whether they are interested in 
taking part in the trial. On receipt of the EOI, the research nurse/HCA/allied health professional (AHP) from 
the Clinical Research Network (CRN) phones the patient to discuss the study further. The CRN is blinded to 
which arm the practices have been randomised to. 
 
 
The CRN informs the central research team which patients have been confirmed as eligible and have verbally 
agreed to participate so they can be sent the relevant patient pack depending on which arm the patient’s GP 
practice is randomised to. All patients receive the same consent forms and questionnaires, but those in the 
intervention arm also receive a bladder diary to be completed before their face-to-face visit. 
 
 
For patients attending practices in the usual care arm, the central research team will send the consent form 
and symptom score questionnaires by post for the patient to complete. 
 
 
For patients attending practices in the intervention arm, the central research team sends the consent form, 
bladder diary and symptom score questionnaires by post. Once the consent forms, bladder diary and 
questionnaires have been returned, the trial research or practice nurse/HCA arrange an appointment for a 
face-to-face consultation to review the bladder diary and symptoms scores and administer the standardised 
manualised intervention(s) as applicable, to the individual patient. 
 
 
For patients in both arms, the return of the completed consent form demonstrates explicit consent to 
participate in the study. 
 
 
All men who enter the study are logged with the central trial office at the University of Bristol (UoB) and given 
a unique Study Number. The patient’s GP is informed by the central study team by letter about the patient’s 
participation in the trial. The GP electronic patient record is updated to record participation. 
 
 
Alongside providing explicit consent to take part in the study, the men will also be asked on the consent form 
if they are willing to consent to (i) being contacted by a qualitative researcher to undertake an interview and 
(ii) being contacted about other research. Declining to consent to these does not disqualify a man from 
participating in the main trial. 
 
 
2.8 Randomisation procedures 
GP practices are the unit of allocation to the two study arms. Practices are randomised on a 1:1 basis to receive 
either the intervention or continue care as usual (control group) by a Bristol Randomised Trials Collaboration 
(BRTC; part of the Bristol Trials Centre) statistician who is blinded to the identity of practices. This is done after 
the practice list searches have been conducted, lists are screened by GPs and mailout uploaded (see section 
2.7). As there are a relatively small number of GP practices in the trial, minimisation is used to allocate 
practices to treatment arms to ensure balance. Allocation is minimised by centre (Bristol and Southampton), 
practice size (numeric variable) and area-level deprivation (Index of multiple deprivation (IMD); numeric 
variable) of the practice. A random element was incorporated in the minimisation procedure such that there 
was a 40% probability that allocation was random. Where allocation was random, there was a 50-50 chance 
of practices being allocated to either arm. 
 
 
While it is common to use lower super output area level (LSOA) deprivation scores to estimate deprivation for 
individuals (using home postcodes to identify the LSOA), it has been shown that middle layer super output 
area level (MSOA) data better reflect the area-level deprivation of GP practices (1). As such, GP practice 
postcodes are mapped onto LSOAs then MSOAs. Population averaged IMD scores (2015) are then calculated 
based on the scores of LSOAs within each MSOA. 
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2.9 Sample size justification 
This study is powered to detect a mean between-group difference of 2 points on our primary outcome of IPSS 
scores at 12 months post-consent. This target difference was chosen because while the recognised minimum 
important difference in IPSS scores is 3.0 (2), men may be bothered by just one symptom (e.g. nocturia). A 




To inform the sample size calculation, a scoping search was conducted with local GP practices within NHS 
Bristol Clinical Commissioning Group (CCG) to gain a sense of the likely number of patients available on their 
lists based on our inclusion and exclusion criteria. This search suggested that an average sized GP practice 
might identify 100 patients. We originally assumed that 50% of these patients would be eligible and of these, 
70% consent, so each practice would consent ~35 eligible patients. Our estimates of eligibility rates, consent 




Based on this, we estimated that 840 patients were needed from at least 24 practices to detect a difference 
in IPSS scores of 2 (common standard deviation of 5: in line with the assumptions made in the Urodynamics 
for Prostate Surgery Trial; Randomised Evaluation of Assessment Methods (UPSTREAM study) (3)) with 90% 
power and significance level 5%. Our estimate incorporated a design effect to account for clustering of effects 
in practices, which assumed that practices would be able to recruit 35 patients each (i.e. mean cluster size of 
35) and that the intra-class correlation between practices would be 0.05 – an estimate in line with results from 
other primary care studies (4). We allowed for up to 30% of men being lost to follow-up. 
 
 
During the early stages of recruitment, however, it became apparent that practices were not consistently 
consenting 35 patients and that the variability in recruitment would necessitate more practices being 
recruited to achieve our objective of 90% power to detect a mean difference in IPSS scores of 2. Using 
information from the numbers and proportions of patients consenting from practices recruited early in the 
trial, and projections regarding practices soon to start recruiting patients, we revised our assumptions and 
assumed that the mean number of patients consented at each practice would be 26 and that the coefficient 
of variation for the mean cluster size between practices would be 0.26. Based on these revised assumptions, 
this increased the number of practices required for the study by 6 and the trial management group agreed to 





Two statisticians support this trial. The senior statistician is blinded throughout the trial. A junior statistician 
will perform all disaggregated analyses according to this statistical analysis plan (SAP) and attends closed 
meetings of the independent data monitoring committee (DMC) as required. The CRN support team is blinded 
to minimise selection and recruitment bias. The remaining members of the study team are blinded to 




2.11 Interim analyses 
No interim analyses were planned. 
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2.12 Trial oversight 
 
2.12.1 Trial management group 
The trial will be managed by a Trial Management Group (TMG), which meets face-to-face/by teleconference 
approximately every 2 months. The TMG is chaired by the Chief Investigator and includes all members of the 
named research team. 
 
 
2.12.2 Trial steering committee 
The role of the Trial Steering Committee (TSC) is to provide the overall supervision of the trial, monitor trial 
progress and conduct and advise on scientific credibility. The membership consists of an independent chair 
(Prof. Peter Bower), together with three other independent members including an independent statistician 
(Prof. Siobhan Creanor) and one patient representative. The trial manager and the Chief Investigator (Prof. 
Marcus Drake) also attend. Observers may also attend, as may other members of the TMG or members of 
other professional bodies, at the invitation of the Chair. The TSC will consider and act, as appropriate, upon 
the recommendations of the Data Monitoring Committee (DMC) or equivalent and ultimately carries the 
responsibility for deciding whether a trial needs to be stopped on grounds of safety or efficacy. It is anticipated 
that the TSC will meet twice a year. 
 
 
2.12.3 Data monitoring committee 
The Data Monitoring Committee (DMC) has an independent chair (Mr Chris Harding), and monitors 
accumulating trial data during the trial and makes recommendations to the TSC as to whether there are any 
ethical or safety issues that may necessitate a modification to the protocol or closure of the trial. It is 
anticipated that the DMC will meet twice a year. 
 
 
In accordance with the Trial Terms of Reference for the DMC, this group is responsible for assessing safety 
and efficacy of the trial. 
 
 
2.13 0Outcome measures 
 
2.13.1 Primary outcome 
The primary endpoint will be the patient-reported IPSS score at 12 months after consent. 
 
 
2.13.2 Secondary outcomes 
• Symptoms: IPSS score at 6 months and ICIQ-UI-SF at 6 and 12 months; 
• Cost-effectiveness from an NHS perspective; 
• Overall quality of life: EuroQol 5-dimension 5-level (EQ-5D-5L); 
• LUT specific quality of life: IPSS Quality of life (IPSS QoL) at 6 and 12 months; 
• Number of related adverse events (identified using medical notes at the end of the study; SAEs are 
reported separately by practices and patients); 
• Number of GP consultations (identified using medical notes at the end of the study); 
• Number of referrals to secondary care (identified using medical notes at the end of the study); 
• Patient perception of their LUTS - Brief Illness Perception Questionnaire (B-IPQ); 
• Patient experiences of the intervention 
 
Cost-effectiveness, EQ-5D-5L and the number of GP consultations are analysed as part of the health economics 
analysis. The patient experiences of the intervention are analysed as part of the qualitative analysis. 
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3. GENERAL ANALYSIS CONSIDERATIONS 
 
3.1 Analysis populations 
The Full Analysis set includes all participants at randomised practices. The primary intention-to-treat (ITT) 
analysis will be conducted using this dataset. 
 
 




Safety analyses will be conducted on all participants at randomised practices according to whether or not the 
participant received the intervention. For the purposes of these analyses, receiving the intervention booklet 
constitutes receiving the intervention. 
 
 
3.2 Derived variables 
The algorithms for the calculation of derived variables in this study are described below: 
 
IPSS The IPSS score is derived from the responses to seven items regarding urinary 
symptoms (incomplete emptying, frequency, intermittency, urgency, weak 
stream, straining and nocturia). For each item, patients choose one of six 
responses indicating increasing severity to describe their symptoms. Responses 
are coded from 0-5. The total score is calculated as the sum of each of the 
responses. The total score ranges from 0 (asymptomatic) to 35 (symptomatic). 
IPSS QoL The eighth item from the IPSS questionnaire relates to the patient’s perception 
of their quality of life (“If you were to spend the rest of your life with your 
urinary condition just the way it is now, how would you feel about that?”). 
Patients are given seven potential responses to choose from, coded 0 
(delighted) to 6 (terrible). 
ICIQ-UI-SF The ICIQ-UI-SF assesses the impact of symptoms of incontinence on quality of 
life and the outcome of treatment. A score is derived from the sum of the 
scores of the first three items: 
• “How often do you leak urine?” There are six potential responses, 
each scored on a scale of 0 (never) to 5 (all of the time). 
• “How much do you usually leak?” There are four potential responses 
coded 0 (none), 2 (small amount), 4 (a moderate amount) and 6 (a 
large amount). 
• “Overall, how much does leaking urine interfere with your everyday 
life?” There are 11 possible responses, each ranging from 0 (not at all) 
to 10 (a great deal). 
 
The IPSS scores will be used to identify the nature of the symptoms patients 
have. Because the IPSS does not cover post-micturition dribble or incontinence, 
the ICIQ-UI-SF will be used to decide if a patient experiences those symptoms. 
The ICIQ-UI-SF incorporates a question asking patients when they experience 
urine leaks. The options are: 
1. Never 
2. Leaks before getting to the toilet 
3. Leaks when coughing or sneezing 
4. Leaks when asleep 
5. Leaks when being physically active/exercising 
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 6. Leaks for no obvious reason 
7. Leaks when having finished urinating and are dressed 
Responses 2 to 6 (which are not mutually exclusive) will categorise someone as 
having incontinence. Option 7 will be used to categorise post-micturition 
dribble. 
EQ-5D-5L The EQ-5D-5L questionnaire comprises five items each having 5-level responses 
coded 1-5. NICE currently advises that the 5-level valuation set for England is 
not recommended for use to derive utilities, instead advising that the validated 
mapping function to the 3-level valuation set be used (5). 
B-IPQ The B-IPQ is comprised of nine items of which the first eight ask patients to 
score each item on a scale of 0-10 regarding their perceptions of how their 
illness affects different aspects of their life. With permissions, we modified it 
slightly to reflect that we wished to enquire about “urinary symptoms” rather 
than “illness”. The questions asked are as follows: 
 
1. How much do your urinary symptoms affect your life? 
2. How long do you think your urinary symptoms will continue? 
3. How much control do you feel you have over your urinary 
symptoms? 
4. How much do you think your treatment can help your urinary 
symptoms? 
5. How much do you experience urinary symptoms? 
6. How concerned are you about your urinary symptoms? 
7. How well do you feel you understand your urinary symptoms? 
8. How much do your urinary symptoms affect you emotionally? 
 
To compute an overall score, items 3, 4, and 7 are reverse scored and added 
to the scores for items 1, 2, 5, 6, and 8. A higher score reflects a more 
threatening view of the urinary symptoms. 
 
Patients were also asked to list in rank-order the three most important factors 
that they believe caused their urinary symptoms. This information will be 




3.3 Procedures for missing data 
In all tables, missing data will be indicated using footnotes. For the primary outcome of IPSS at 12 months, we 
will use descriptive statistics to describe the baseline characteristics of patients who do and do not have 
missing primary outcome data. Missing primary outcome data will also be imputed as part of a sensitivity 
analysis described in section 6.4.5. Missing secondary outcome data will not be imputed. 
 
 
3.4 Study centre effects 
Randomisation of practices minimises on centre and all analyses will adjust for centre (Bristol or Southampton) 
and all other minimisation variables using fixed effects. 
 
 
3.5 Potential outliers 
Prior to commencing the formal analysis, the trial statistician will use graphs and descriptive statistics to 
identify potential outliers in the data. These will be queried with the trial manager who will verify hard copy 
questionnaires to confirm whether or not they are data entry mistakes. Where outlier values prove not to be 
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3.6 Visit windows 
All questionnaires will be analysed regardless of when they are returned. We will, however, describe the mean 
time between baseline and receipt of questionnaires. 
 
 




The flow of patients and practices (clusters) through the trial will be summarised in a CONSORT diagram that 
will include the eligibility, reasons for exclusion, numbers of patients consenting, numbers of practices 
randomised to the two treatment groups, losses to follow up and the numbers analysed for the primary 
outcome. 
 
TRIUMPH also contains an internal pilot stage which will be described in accordance to the guidelines set out 
in the CONSORT extension for pilot and feasibility studies. 
 
 
4.2 Baseline characteristics 
Baseline characteristics of patients and practice characteristics will be compared between the two arms by 
reporting relevant summary statistics in order to describe the study sample and determine whether any 
potentially influential imbalance occurred by chance. Baseline characteristics will be summarised using means 
(SD), medians (inter-quartile range; IQR), ranges (minimum and maximum) or number (%) depending on the 
nature of the data and its respective distribution. If the baseline characteristics of the groups differ by more 
than 10%, or half a standard deviation, then the effect of this variable on the outcome (primary and secondary) 
will be investigated in sensitivity analyses. 
 
 
5. ASSESSMENT OF STUDY QUALITY 
 
5.1 Eligibility checks 
The numbers of patients and reasons for exclusions will be described. 
 
 
5.2 Selection bias 
To assess how randomised patients differed from the wider group of men with LUTs at participating practices, 
we will report the mean (SD) age and age range of participants at the time of GP screening, of the following 
groups: 
• Men who were identified as having LUTS through the GP records search and manual screening by 
GPs and were invited to participate. Within this group we will describe separately those who returned 
the EOI and indicated they were potentially interested, those who at this stage said they were not 
interested, and those who did not return the EOI; 
• Men who were invited for further screening by the CRNs. Within this group we will describe 
separately those who were deemed eligible and willing to participate in the study at this stage, those 
who were eligible and not willing, those who were deemed ineligible and those who were not 
contactable by the CRN; 
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5.3 Data validation 
Once the data are downloaded by the trial statistician, internal consistency checks will be performed by them 
in preparing the data for analysis in Stata. These checks aim to identify spurious values or inconsistencies in 
responses. When inconsistencies are identified, these will be reported to the trial manager who will verify 
against the completed forms. 
 
 
5.4 Study completion 
Final patient questionnaires are sent at 12-month post-consent and data on primary care consultations and 
referrals are collected until 12-months post-consent. For the latter, these data are collected by the practices 
using a standardised medical records search conducted at least one month after their last patient reaches 
their 12-month follow-up. 
 
 
5.5 Protocol deviations 
There are no prospective, planned deviations or waivers to the protocol. Accidental protocol deviations will 
be recorded and the frequency of each type of deviation will be tabulated by treatment allocation with full 
details given in separate listings. 
 
 
At the patient level, we note that patients in the intervention arm might not have: 
• Received the intervention booklet; 
• Received follow-up contact at the scheduled time points (1, 4 and 12 weeks); 
• Received follow-up contact in the protocolised format; 
• Received any follow-up contact 
All of these will be reported. 
 
 
6. ANALYSIS OF EFFECTIVENESS 
Data will be analysed and reported in accordance with CONSORT principles and its extensions for cluster 
randomised trials and patient reported outcome measures. The internal pilot will be reported in accordance 
with CONSORT principles and its extension for pilot and feasibility studies. 
 
 
Stata version 15 (or higher) will be used for all TRIUMPH analyses. Two-tailed tests will be used with effect 
estimates, 95% confidence intervals (CI) and p-values presented. A significance level of 5% will be used and 
no adjustment will be used for multiple testing. Analyses using regression models will adjust for minimisation 
variables as well as baseline values of the outcome studied. The primary approach for analysis will be on an 




6.1 Mis-randomised practices 
Patients will be analysed according to the arm to which their practice was randomised. 
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6.2 Summary of primary and secondary endpoints 
The primary and secondary endpoints are summarised below: 
 




IPSS Baseline and 12 
months 
The total score is a 
discrete number with 







IPSS Baseline and 6 
months 




ICIQ-UI-SF Baseline, 6 and 
12 months 
The score is a discrete 
number with higher 
scores reflecting worse 
quality of life. 
0-21 
LUTS specific quality of 
life 
IPSS QoL Baseline, 6 
months and 12 
months 
The total score is a 
discrete number with 




Overall quality of life EQ-5D-5L Baseline only 
(analysis at 6 
and 12 months is 




with larger values 
reflecting better quality 
of life. 
-0.594 - 1 
Patient perception of 
their LUTS 
B-IPQ Baseline, 6 and 
12 months 
A higher score reflects 
a more threatening 
view of their symptoms 
0-90 
Number of GP 
consultations (number 
in the previous 12 
months) 
- Baseline, 
analysis at 12 
months is 
included in the 
health economic 
analysis) 
Discrete variable Minimum of 0 
Number of referrals to 
secondary care in the 
previous 12 months 
- Baseline and 12 
months 
Binary variable coded 0 
and 1 at the individual 
level based on whether 
the patient did not (0) 
or did (1) have a 
referral to secondary 





6.3 Primary analysis 
The primary outcome is IPSS score collected at 12 months post-consent. It will be described in each treatment 
group using means and standard deviations. Comparisons between treatment arms will be made using a 
mixed-effect multilevel linear model (individual patients (level 1) nested within GP practices (level 2)) and 
adjusting for patient-level baseline IPSS scores and practice-level variables used in the randomisation. The 
results will be presented as the mean between-group difference, corresponding 95% confidence interval and 
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P-value. The results adjusted only for baseline scores will also be presented. The intra-class correlation (ICC) 
will be reported, with a 95% confidence interval. 
 
 
We will check the normality assumptions of the residuals from the fixed part of the multi-level model and the 
random effects at the cluster level using graphs. The choice of covariance structure will be decided upon based 
on a review of the data. Alternative methods of analysis will be considered if the assumptions of the model 
are not be met. This might include, for example, using a bootstrap framework to estimate confidence intervals. 
 
 
6.4 Sensitivity analyses 
A number of analyses are proposed to assess the sensitivity of the primary analysis to various assumptions. 
These are described below. Sensitivity analyses will be presented alongside those of the primary analysis in 
order for them to be compared and contrasted. As these will be exploratory in nature, 95% confidence 
intervals and p-values will be presented, but will be interpreted with due caution. 
 
 
6.4.1 Imbalance between treatment groups 
Should there be evidence of imbalance between treatment groups on important baseline characteristics as 
described in section 4.2, sensitivity analyses will be conducted where the primary analysis is repeated, 
adjusting for variables showing an imbalance. This sensitivity analysis will be performed for the primary 
outcome as well as all secondary outcomes. 
 
 
6.4.2 Clustering by nurse/HCA 
Exploring whether there is evidence of clustering by the individual nurse/HCA delivering care (in the 
Intervention arm) is complicated by the fact that where research nurses were invited to deliver the 
intervention, individual research nurses may work across multiple practices. As such, nurses/HCAs are not 
clustered within (single) practices. Furthermore, within a given practice, the intervention may be delivered by 
more than one nurse/HCA. 
In an attempt to explore this, we will group the patient-level data into clusters based on the combination of 
practice where the patient is registered and nurse/HCA delivering the intervention (first visit). We will then 
repeat the primary analysis of the IPSS at 12 months using a single random effect for this level of clustering 
and compare the results with those of the primary analysis. 
In the event that this modelling proves infeasible, we will consider a cross-classified multi-level model 
approach which incorporates the fact that nurses/HCAs do not nest neatly within practices. We will also 
calculate the mean IPSS at 12 months for each of these nurse/HCA-practice clusters and explore descriptively 
how the means compared between individual nurses/HCAs. 
 
 
6.4.3 Per protocol analysis 
Based on the protocol deviations outlined in section 5.5, we will conduct five separate per protocol analyses 
of the primary outcome: 
• Excluding those in the intervention arm who received no intervention booklet by the time of the 
primary outcome measure at 12 months and had none of the follow-up contacts at 1, 4 and 12 weeks; 
• Excluding those in the intervention arm who received the intervention booklet by the time of the 
primary outcome measure at 12 months, but only had 2 of the 3 follow-up contact visits (regardless 
of whether or not these were early or late); 
• Excluding those in the intervention arm who received the intervention booklet by the time of the 
primary outcome measure at 12 months and had only 1 follow-up contact (regardless of whether or 
not this was early or late); 
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• Excluding those in the intervention arm who received their intervention booklet by the time of the 
primary outcome measure at 12 months but had no follow-up contact; 
• Excluding those in the intervention arm who did not receive their follow-up contact in the 
protocolised format (i.e. by phone, post or email) 
 
 
6.4.4 Complier average causal effect (CACE) analysis 
Recognising the inherent bias in estimates derived from per protocol analyses, we will also conduct a CACE 
analysis for the primary outcome. Compliers can only be observed amongst those randomised to the 
intervention arm. In the first instance, compliers will be defined as those who will have received the 
intervention booklet by the time of the primary outcome follow-up. Non-compliers will be defined as those 
who have not received the booklet at all or received it after the primary outcome time point. These categories 
will be compared in terms of key baseline characteristics. The CACE estimates will be obtained using 
instrumental variable regression including the same variables used in the primary analysis with randomised 
group as the instrumental variable and the indicator variable for compliance. 
 
 
6.4.5 Exclusion of patients later found to be ineligible 
Patients in the study who, after consenting and providing data, are found to be ineligible will be included in 





6.4.6 Impact of COVID-19 on IPSS scores 
By the time the COVID-19 outbreak was declared a pandemic by the World Health Organisation on 11 March 
2020, the study had already reached its target recruitment and was no longer recruiting. All patients will have 
reached at least 7 months of follow-up by then and many will have completed final follow-up. The only change 
required to trial procedures was to move to online questionnaires for the 12-month follow-up. It is estimated 
that 45% of patients will have had their final follow-up after the start of the pandemic. 
 
Recognising that trial participation and symptom reporting may have been impacted by the outbreak and 
subsequent lock-down, we will: 
 
• Explore whether there were differences in the proportions of missing data for the primary 
outcome (IPSS at 12 months) before and after 11 March 2020; 
 
• Explore whether IPSS scores at 12 months differed depending on whether data were collected 
before or during the COVID-19 pandemic. Scores before and after 11 March 2020 will be 
described using descriptive statistics and the primary analysis model will be re-fitted including a 





6.4.7 Missing outcome data 
We will explore patterns of missing IPSS responses at 12 months and consider possible mechanisms for this. 
This will include comparing the baseline characteristics of patients with and without IPSS data at 12 months. 
Based on these and observed data, appropriate methods for imputing missing data will be considered in 
sensitivity analyses, including both “best” (lowest IPSS score possible) and “worst” (highest IPSS score 
possible) case scenarios. Where assumptions are met, this may include multiple imputation by chained 
equations. Imputation models will include baseline, 6-month IPSS data (as available), allocated treatment arm, 
variables used in the randomisation as well as other variables such as baseline and auxiliary covariates 
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informative of missingness. To allow for clustering in Stata, imputations will be performed separately for each 
practice where possible. 
 
 
6.4.8 Impact of outliers 
As outlined in section 3.5, we will check outlier values to ensure that they are not, in fact, data entry mistakes. 
If after data checking outliers remain in any of the variables used in the primary analysis we will assess the 
impact of these outliers by re-fitting the primary analysis model excluding outlier values. 
 
 
6.5 Secondary outcomes analyses 
The approach for analysis of the secondary outcomes will be on an ITT basis defined as analysing all 
participants according to the group their practice was randomised to. 
 
 
IPSS symptom scores at 6 months will be analysed in the same manner as the primary outcome using a linear 
mixed model (individual patients (level 1) nested within GP practices (level 2)) adjusting for baseline scores 
and minimisation variables. A separate repeated measures analysis using a linear mixed model (6-monthly 
observations of IPSS scores (level 1), nested within participants (level 2) and nested within GP practices (level 
3)) will also be conducted to incorporate all time points. ICIQ-UI-SF, IPSS QoL and B-IPQ at 6 and 12 months 
will be studied in the same manner. 
 
 
We will check the normality assumptions of the residuals from the fixed part of these multi-level models and 
the random effects at the cluster level using graphs. Appropriate transformations will be considered if the 
assumptions of the model are not met. The choice of covariance structure will be decided upon based on a 
review of the data. 
 
Whether or not a patient has a referral to secondary care will be studied using a logistic mixed model with 
individual patients nested within GP practices. The model will adjust for minimisation variables and whether 
or not the patient had a referral pre-baseline. 
 
 
6.6 Subgroup analyses 
Four pre-specified subgroup analyses will be performed. In all cases effect modification will be assessed by 
including an interaction term in the regression model and formal tests of interaction will be performed to test 
whether the treatment effect differs between these groups. As with all other analyses, a significance level of 
5% will be used. These analyses, however, are not statistically powered and will be interpreted with due 
caution as exploratory. 
 
 
6.6.1 Nature of LUTS at baseline 
The effects of the intervention may differ between groups of patients according to the nature of LUTS 
experienced at baseline. The ratio of the IPSS voiding sub-score to the storage sub-score (IPSS-V/S ratio) has 
been used to describe the relative dominance of voiding to storage LUTS (6). Subgroup analysis will be carried 
out to assess the difference in treatment effect on the primary outcome according to the voiding/storage sub- 
score ratio reported at baseline. 
 
 
6.6.2 Intervention delivery 
We will explore if the effect of the intervention differed according to whether the practice nurse or TRIUMPH 
study nurse delivered the intervention to the patient. This will be explored by including an interaction term in 
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6.6.3 Method of contact 
Patients in the intervention arm specified how they preferred to be contacted by the research team for their 
intervention follow-up contacts. This might be by telephone or text, for example. We will report the frequency 
of each preferred mode of contact as well, the model of contact used and how often this differed. We will 
explore whether the effect of the intervention differed by model of contact by including a “preferred method 




To explore the possibility that the number of nurse/HCA contacts modifies the effect of the intervention we 
will create a “dose” variable equal to the number of nurse/HCA contacts patients at the intervention practices 
received (0-3). We will then repeat the primary analysis using the “dose” variable as the treatment variable. 
 
 
6.7 Exploratory analyses 
We will conduct a small number of further exploratory analyses as described below. 
 
 
6.7.1 Descriptive analyses 
Among patients in the intervention arm, we will describe which sections of the treatment booklet they were 
advised to read according to the categories of LUTS patients present with at baseline (based on IPSS and ICIQ- 
UI-SF scores). We will also explore how the EQ-5D-5L responses at baseline relate to the IPSS-QoL at baseline. 
 
 
6.7.2 IPSS severity banding 
Existing severity bands for the IPSS score have been developed for patients referred for specialist urological 
care and in mixed populations of patients with and without LUTS. Our population of men – all experiencing 
bothersome LUTS and being treated in primary care – may not report similar illness patterns. We aim to 
explore whether different bandings may be more appropriate in this group. 
 
 
Another trial recently considered this question within their own patient group (7). We will adopt a similar 
approach to derive cut-off points in the IPSS for banding by using the sensitivity and specificity levels derived 
from the receiver operating characteristic curve plotted using IPSS quality of life scores. We will describe 
if/how new bandings differ to previously established bandings. 
 
 
6.7.3 Characterising patients whose symptoms are not captured on the IPSS 
The IPSS questionnaire is not able to capture all LUTS and patients may have low IPSS scores despite having 
high ICIQ-UI-SF scores due to leakage. Qualitative interviews conducted at the end of the pilot phase of the 
study may help us to understand how the IPSS and ICIQ-UI-SF questionnaires are completed when leakage is 
the only symptom present. 
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7. ANALYSIS OF SAFETY 
All related adverse events will be tabulated by whether or not the patient had received the intervention (see 
section 3.1). The number of events, number of patients having at least one event and the number of patients 
with more than one event will be tabulated. Serious adverse events (SAEs) will also be listed according to 
whether or not the patient received the intervention. 
 
 
8. CHANGES TO THE SAP 










Brief summary of changes Changes made 
before or after the 
statistician analysing 
the data was 
unblinded 
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9. FINAL REPORT TABLES AND FIGURES (SUBJECT TO CHANGE) 
9.1 Populations: Tables, figures and listings detailing the study population 
 
Figure 1 CONSORT flow diagram 
Figure 2 Cumulative number of practices randomised over time 
Figure 3 Cumulative patient recruitment over time 
Table 1 Patient recruitment by centre and practice 
Table 2 Patient withdrawals from the study 
Table 3 Practice level characteristics 
Table 4 Follow-up rates by practice 
Table 5 Timing of questionnaire completion at all follow-ups 
Table 6 Comparison of the ages of men identified as having LUTS who were invited to participate 
Table 7 Comparison of the ages of men identified who were invited to have further screening by the 
CRNs 
Table 8 Comparison of the ages of men eligible and willing to participate at the CRN stage of 
screening 
Table 9 Intervention delivery 
 
 
9.2 Baseline data: Summary tables of baseline information 
 
Table 10 Patient characteristics at baseline 
Table 11 Electronic medical records search: relevant prescriptions issued to patients in the 3 months 
pre-baseline 
Table 12 Baseline characteristics associated with missing IPSS data at 6 months 
Table 13 Baseline characteristics associated with missing IPSS data at 12 months 
 
9.3 Outcomes: Summary data and treatment estimates 
 
Table 14 Primary outcome: mean and difference in mean patient-reported urinary symptom (IPSS) 
score at 12 months 
Table 15 Sensitivity analysis: Comparison of results from the primary ITT analysis, per protocol 
analyses and CACE analysis (IPSS score at 12 months) 
Table 16 Sensitivity analysis: comparison of demographics between compliers and non-compliers 
Table 17 Sensitivity analysis: comparison of results of primary analysis using the ITT population and 
analysis excluding those patients later found to be ineligible (IPSS score at 12 months) 
Table 18 Sensitivity analysis: comparison of results of primary analysis with and without adjusting for 
the COVID-19 pandemic (IPSS score at 12 months) 
Table 19 Sensitivity analysis: comparison of results of ITT analysis of complete cases with ITT analysis 
where missing data were imputed for IPSS scores (12 months) 
Table 20 Sensitivity analysis: comparison of results of primary analysis with and without the 
exclusion of outlier values (IPSS score 12 months) 
Table 21 Secondary outcome: mean and difference in mean patient-reported urinary symptom (IPSS) 
score at 6 months 
Table 22 Mean and difference in mean patient-reported urinary symptom (IPSS) score using repeated 
measures data at 6 and 12 months 
Table 23 Secondary outcome: mean and difference in mean patient-reported urinary symptoms 
(ICIQ-UI-SF) score at 6 and 12 months 
Table 24 Secondary outcome: mean and difference in mean LUTS specific quality of life (IPSS QoL) at 6 
and 12 months 
Table 25 Secondary outcome: mean and difference in mean score of patient perception of LUTS (B- 
IPQ) at 6 and 12 months 
Table 26 Secondary outcome: percentage and OR of referral to secondary care (urology) 
Figure 4 Relationship between EQ-5D-5L and IPSS-QoL at baseline 
 
9.4 Safety data: Summary tables and listings of all adverse events and serious adverse events 
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Table 27 Related adverse events identified from GP records search 
Table 28 All related adverse events including severity classification 
Table 29 All related adverse events by patient 
Table 30 List of individual SAEs 
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9.1 Populations: Tables, figures and listings detailing the study population 
Figure 1: CONSORT flow diagram 
 
Practices expressing interest in study (n=XX) 
Practices performing an initial search (n=XX) 
 
 
Participating practices (n=XX); Patient population (n=XXXXXX) 
 
Excluded practices due to 
insufficient patients w/LUTS 
(n=XX) 
List of other reasons (n=XX) 
 
 
Patients manually screened by GPs (n=XXXX) 
Patients eligible at database search (n=XXXX) 
Patients ineligible at 
database search (n=XXXXXX) 
 
Patients not screened (n=XXX) 
 
Patients eligible at manual screening (n=XXXX) 





Practices randomised to the intervention (n=XX) 
Patients eligible at manual screening (n=XXXX) 
Practices randomised to usual care (n=XX) 
Patients eligible at manual screening (n=XXXX) 
 
Patients not included in mail out (n=XXX) Patients not included in mail out (n=XXX) 
 
Patients included in mail out (n=XXX) Patients included in mail out (n=XXX) 
 
EOI not returned by patient (n=XXX) EOI not returned by patient (n=XXX) 
 
Patient returned EOI (n=XXX) Patient returned EOI (n=XXX) 
 
Patient declined in EOI (n=XXX) Patient declined in EOI (n=XXX) 
 
Patient interested in EOI (n=XXX) Patient interested in EOI (n=XXX) 
 
Patient excluded at CRN screening (n=XXX) 
Ineligible (n=XXX); Unwilling (n=XXX) 
Uncontactable (n=XXX) 
Patient excluded at CRN screening (n=XXX) 
Ineligible (n=XXX); Unwilling (n=XXX); 
Uncontactable (n=XXX) 
 
Patients eligible at CRN screening (n=XXX) Patients eligible at CRN screening (n=XXX) 
 
Patients excluded (n=XXX) 
Did not consent (n=XXX) 
Patients excluded (n=XXX) 
Did not consent (n=XXX) 
 
Patients consented (n=XXX) 
Patients providing baseline IPSS (n=XXX) 
Patients consented (n=XXX) 
Patients providing baseline IPSS (n=XXX) 
 
6-month follow-up 
Practices (n=XX); Patients (n=XXX) 
Patients providing complete IPSS data (n=XXX) 
Patients lost to follow-up (n=XXX) 
Reasons listed 
6-month follow-up 
Practices (n=XX); Patients (n=XXX) 
Patients providing complete IPSS data (n=XXX) 




Practices (n=XX); Patients (n=XXX) 
Patients providing complete IPSS data (n=XXX) 
Patients lost to follow-up (n=XXX) 
Reasons listed 
12-month follow-up 
Practices (n=XX); Patients (n=XXX) 
Patients providing complete IPSS data (n=XXX) 
Patients lost to follow-up (n=XXX) 
Reasons listed 
 
Patients included in primary analysis (n=XXX); Patients excluded from primary analysis (n=XXX) 
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Figure 2: Cumulative number of practices randomised over time 
(x axis: time; y-axis: cumulative number of practices recruited) 
 
Figure 3: Cumulative patient recruitment over time 
(x axis: time; y-axis: cumulative number of patients recruited) 
 
Table 1: Patient recruitment by centre and practice 
 
























Bristol        
Bristol        
Bristol        
Bristol        
Bristol        
Bristol        
Bristol        
Bristol        
Bristol        
Bristol        
Bristol        
Bristol        
Bristol        
Bristol        
Bristol        
Bristol        
Southampton        
Southampton        
Southampton        
Southampton        
Southampton        
Southampton        
Southampton        
Southampton        
Southampton        
Southampton        
Southampton        
Southampton        
Southampton        
Across Bristol practices      
Across Southampton practices      
 




Arm Date Months since 
consent 
Reason Withdrawal from complying with the 
trial treatment and/or withdrawal 
from providing further trial data 
      
 
Table 3: Practice level characteristics 
 










based on surgery 
postcode 
Bristol       
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Bristol       
Bristol       
Bristol       
Bristol       
Bristol       
Bristol       
Bristol       
Bristol       
Bristol       
Bristol       
Bristol       
Bristol       
Bristol       
Bristol       
Bristol       
Southampton       
Southampton       
Southampton       
Southampton       
Southampton       
Southampton       
Southampton       
Southampton       
Southampton       
Southampton       
Southampton       
Southampton       
Southampton       
Mean (SD) across intervention practices    
Mean (SD) across usual care practices    
 
Table 4: Follow-up rates by practice 
 
Centre Arm Practice 
ID 
Total number of 
patients consented 
Follow-upa; n (%) 
6 months 12 months 
Bristol      
Bristol      
Bristol      
Bristol      
Bristol      
Bristol      
Bristol      
Bristol      
Bristol      
Bristol      
Bristol      
Bristol      
Bristol      
Bristol      
Bristol      
Bristol      
Southampton      
Southampton      
Southampton      
Southampton      
Southampton      
Southampton      
Southampton      
Southampton      
Southampton      
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Southampton      
Southampton      
Southampton      
Southampton      
Across intervention practices    
Across usual care practices    
a For the purpose of this analysis a patient is considered to have provided follow-up data if they returned any of the 
questionnaires for that follow-up period regardless of missing data for individual outcomes. The denominator for proportions 
reported is the number of patients consented 
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Table 5: Timing of questionnaire completion at all follow-ups 
 
Follow-up Number of questionnaires returned Mean (months) since baseline SD 
Intervention practices 
6 months    
12 months    
Usual care practices 
6 months    
12 months    
 
Table 6: Comparison of the ages of men identified as having LUTS who were invited to participate 
 N na Mean SD Min, Max 
Returned EOI and 
interested 
     
Returned EOI and 
were not 
interested 
     
Did not return EOI      
All groups 
combined 
     
a Number with available data 
 
 
Table 7: Comparison of the ages of men identified who were invited to have further screening by the CRNs 
 
 N na Mean SD Min, Max 
Eligible at CRN screening and willing to 
participate in the study 
     
Eligible at CRN screening and not willing 
to participate in the study 
     
Ineligible at CRN screening      
Not contactable by the CRN      
All groups combined      
a Number with available data 
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Table 8: Comparison of the ages of men eligible and willing to participate at the CRN stage of screening 
 
 All practices Intervention practices Usual care practices 
 N na Mean SD Min, Max N na Mean SD Min, Max N na Mean SD Min, Max 
Eligible men who 
consented to 
participate 
               
Eligible men who 
did not consent to 
participate 
               
Both groups 
combined 
               
a Number with available data 
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of    
patients 
consented 
Visit 1-week F/U 4-week F/U 12-week F/u 
Number of 
patients receiving 






Number of patients 







Number of patients 
receiving this stage 





Number of patients 
receiving this stage 




up; n (%) 
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
Across Bristol practices          
Across Southampton practices          
STATISTICAL ANALYSIS PLAN 
TRIUMPH 
Version 1 30 31 July 2020 
 
 
9.2 Baseline data: Summary tables of baseline information 
Table 10: Patient characteristics at baseline 
 Intervention Usual care 
na  na  
Total number of participants; n     
Demographic characteristics 




Mixed/Multiple ethnic groups 
Asian/Asian British 
Other ethnic group 
Disclosure declined 
    







    
IMD score; median (IQR) [min – max]     
IMD quintile ; n(%) 




Quintile 5 (least deprived) 
    
Clinical characteristics 
Height (cm); mean (SD) [min – max]     
Weight (kg); mean (SD) [min – max]     
Electronic records search data 
Number of co-morbidities; n(%) 
None 
One 
More than 1 
    
Most recent urine analysis results in the 6 
months pre-baseline; n(%) 
Abnormal 
    
Kidney function: most recent eGFR 
(ml/min/1.73m2) measure in the 6 months 
pre-baseline 
 
Number of patients with an eGFR measure 
eGFR: mean (SD) 
eGFR: median (IQR) 
eGFR: min - max 
    
Chronic kidney disease (CKD) stages based 
on most recent eGFR in the 6 months pre- 
baseline; n(%) 
≥90 ml/min/1.73m2 (normal) 
90-60 ml/min/1.73m2 (CKD stages G1-G2) 
30-59 ml/min/1.73m2 (CKD stage G3) 
<30 ml/min/1.73m2  (CKD stages G4- G5) 
    
Number of GP consultations in the 12 
months before baseline 
Mean (SD) 
Median (IQR) 
[min – max] 
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More than one 
    
Patient reported symptoms and quality of life 








    
Total IPSS score; mean (SD) [min – max]     
IPSS QoL score; mean (SD) [min – max]     
ICIQ-UI-SF total score; mean (SD) [min – 
max] 
    
ICIQ-UI-SF: when does urine leak? n (%) 
Never 
Leaks before you can get to the toilet 
Leaks when you cough/sneeze 
Leaks when you are asleep 
Leaks when you are physically active 
Leaks when you have finished urinating/ are 
dressed 
Leaks for no obvious reason 
Leaks all of the time 
    
EQ-5D-5L utility score; mean (SD) [min – 
max] 
    
EQ5D visual analogue score; mean (SD) [min 
– max] 
    
B-IPQ total score; mean (SD) [min – max]     




  N/A N/A 
a Number of patients providing non-missing data at baseline 
 
 
Table 11: Electronic medical records search: relevant prescriptions issued to patients in the 3 months pre-baseline 
 
 Intervention Usual care 
Total number of patients   
Number of patients for whom electronic 
medical records data were available 
  
 Number of patients having at least 
one prescription (%) 
Number of patients having at least 
one prescription (%) 
List of medications as observed   
…   




Table 12: Associations between baseline characteristics and missing IPSS data at 6 months 
 
 Missing Present p-value 
na  na  
Total number of participants; n      
Treatment arm; n(%) 
Intervention 
Usual care 
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Demographic characteristics  




Mixed/Multiple ethnic groups 
Asian/Asian British 
Other ethnic group 
Disclosure declined 
     







     
IMD score; median (IQR) [min – max]      
IMD quintile ; n(%) 




Quintile 5 (least deprived) 
     
Clinical characteristics  
Height (cm); mean (SD) [min – max]      
Weight (kg); mean (SD) [min – max]      
Electronic records search data  
Number of co-morbidities; n(%) 
None 
One 
More than 1 
     
Most recent urine analysis results in the 6 
months pre-baseline; n(%) 
 
Abnormal 
     
Kidney function: most recent eGFR 
(ml/min/1.73m2) measure in the 6 months 
pre-baseline 
 
Number of patients with an eGFR measure 
eGFR: mean (SD) 
eGFR: median (IQR) 
eGFR: [min – max] 
     
Chronic kidney disease (CKD) stages based 
on most recent eGFR in the 6 months pre- 
baseline; n(%) 
≥90 ml/min/1.73m2 (normal) 
90-60 ml/min/1.73m2 (CKD stages G1-G2) 
30-59 ml/min/1.73m2 (CKD stage G3) 
<30 ml/min/1.73m2  (CKD stages G4- G5) 
     
Number of GP consultations in the 12 
months before baseline 
Mean (SD) 
Median (IQR) 
[min – max] 
     




More than one 
     
Medications at baseline; n(%) 
listed 
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Patient reported symptoms and quality of life  








     
Total IPSS score; mean (SD) [min – max]      
IPSS QoL score; mean (SD) [min – max]      
ICIQ-UI-SF total score; mean (SD) [min – max]      
ICIQ-UI-SF: when does urine leak? n (%) 
Never 
Leaks before you can get to the toilet 
Leaks when you cough/sneeze 
Leaks when you are asleep 
Leaks when you are physically active 
Leaks when you have finished urinating/ are 
dressed 
Leaks for no obvious reason 
Leaks all of the time 
     
EQ-5D-5L utility score; mean (SD) [min – max]      
EQ5D visual analogue score; mean (SD) [min 
– max] 
     
B-IPQ total score; mean (SD) [min – max]      




     
a Number of patients providing non-missing data at baseline 
 
 
Table 13: Associations between baseline characteristics and missing IPSS data at 12 months 
 
 Missing Present p-value 
na  na  
Total number of participants; n      
Treatment arm; n(%) 
Intervention 
Usual care 
     
Demographic characteristics  




Mixed/Multiple ethnic groups 
Asian/Asian British 
Other ethnic group 
Disclosure declined 
     







     
IMD score; median (IQR) [min – max]      
IMD quintile ; n(%) 
Quintile 1 (most deprived) 
Quintile 2 
Quintile 3 
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Quintile 5 (least deprived) 
     
Clinical characteristics  
Height (cm); mean (SD) [min – max]      
Weight (kg); mean (SD) [min – max]      
Electronic records search data  
Number of co-morbidities; n(%) 
None 
One 
More than 1 
     
Most recent urine analysis results in the 6 
months pre-baseline; n(%) 
Abnormal 
     
Kidney function: most recent eGFR 
(ml/min/1.73m2) measure in the 6 months 
pre-baseline 
 
Number of patients with an eGFR measure 
eGFR: mean (SD) 
eGFR: median (IQR) 
eGFR: [min – max] 
     
Chronic kidney disease (CKD) stages based 
on most recent eGFR in the 6 months pre- 
baseline; n(%) 
≥90 ml/min/1.73m2 (normal) 
90-60 ml/min/1.73m2 (CKD stages G1-G2) 
30-59 ml/min/1.73m2 (CKD stage G3) 
<30 ml/min/1.73m2  (CKD stages G4- G5) 
     
Number of GP consultations in the 12 
months before baseline 
Mean (SD) 
Median (IQR) 
[min – max] 
     




More than one 
     
Medications at baseline; n(%) 
listed 
     
Patient reported symptoms and quality of life  








     
Total IPSS score; mean (SD) [min – max]      
IPSS QoL score; mean (SD) [min – max]      
ICIQ-UI-SF total score; mean (SD) [min – max]      
ICIQ-UI-SF: when does urine leak? n (%) 
Never 
Leaks before you can get to the toilet 
Leaks when you cough/sneeze 
Leaks when you are asleep 
Leaks when you are physically active 
Leaks when you have finished urinating/ are 
dressed 
Leaks for no obvious reason 
Leaks all of the time 
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EQ-5D-5L utility score; mean (SD) [min – max]      
EQ5D visual analogue score; mean (SD) [min 
– max] 
     
B-IPQ total score; mean (SD) [min – max]      
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Table 14: Primary outcome: mean and difference in mean patient-reported urinary symptom (IPSS) score at 12 months 
 




95% CI p-value Difference in 
meansb 
95% CI p-value Difference 
in meansc 
95% CI p-value 
Intervention              
Usual care     
Total N     
ICC (95% CI)    
a ITT analysis adjusted for baseline IPSS score and minimisation variables 
b ITT analysis additionally adjusted for variables that show an imbalance between treatment groups at baseline 
c ITT analysis adjusted only for baseline IPSS score 
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Table 15: Sensitivity analysis: Comparison of results from the ITT analysis, per protocol analyses and CACE analysis 
(IPSS score at 12 months) 




95% CI p-value 
ITT        
Per protocol: Excluding those in the 
intervention arm who received no 
intervention booklet by the time of the 
primary outcome measure at 12 months 
and had none of the follow-up contacts 
       
Per protocol: Excluding those in the 
intervention arm who received the 
intervention booklet by the time of the 
primary outcome measure at 12 months, 
but only had 2 of the 3 follow-up contact 
visits 
       
Per protocol: Excluding those in the 
intervention arm who received the 
intervention booklet by the time of the 
primary outcome measure at 12 months 
and had only 1 follow-up contact 
       
Per protocol: Excluding those in the 
intervention arm who received their 
intervention booklet by the time of the 
primary outcome measure at 12 months 
but had no follow-up contact 
       
Per protocol: Excluding those in the 
intervention arm who did not receive their 
follow-up contacts in the protocolised 
format 
       
CACE analysis        
a Analysis adjusted for baseline IPSS score and randomisation variables 
 
Table 16: Sensitivity analysis: comparison of demographics between compliers and non-compliers 
 Compliers Non-compliers p-value 
na  na  
Total number of participants; n      
Demographic characteristics  




Mixed/Multiple ethnic groups 
Asian/Asian British 
Other ethnic group 
Disclosure declined 
     







     
IMD score; median (IQR) [min – max]      
IMD quintile; n(%) 




Quintile 5 (least deprived) 
     
Clinical characteristics  
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Height (cm); mean (SD) [min – max]      
Weight (kg); mean (SD) [min – max]      
Electronic records search data  
Number of co-morbidities; n(%) 
None 
One 
More than 1 
     
Most recent urine analysis results in the 6 
months pre-baseline; n(%) 
Abnormal 
     
Kidney function: most recent eGFR 
(ml/min/1.73m2) measure in the 6 months 
pre-baseline 
 
Number of patients with an eGFR measure 
eGFR: mean (SD) 
eGFR: median (IQR) 
eGFR: [min – max] 
     
Chronic kidney disease (CKD) stages based 
on most recent eGFR in the 6 months pre- 
baseline; n(%) 
≥90 ml/min/1.73m2 (normal) 
90-60 ml/min/1.73m2 (CKD stages G1-G2) 
30-59 ml/min/1.73m2 (CKD stage G3) 
<30 ml/min/1.73m2  (CKD stages G4- G5) 
     
Number of GP consultations in the 12 
months before baseline 
Mean (SD) 
Median (IQR) 
[min – max] 
     




More than one 
     
Medications at baseline; n(%) 
listed 
     
Patient reported symptoms and quality of life  








     
Total IPSS score; mean (SD) [min – max]      
IPSS QoL score; mean (SD) [min – max]      
ICIQ-UI-SF total score; mean (SD) [min – max]      
ICIQ-UI-SF: when does urine leak? n (%) 
Never 
Leaks before you can get to the toilet 
Leaks when you cough/sneeze 
Leaks when you are asleep 
Leaks when you are physically active 
Leaks when you have finished urinating/ are 
dressed 
Leaks for no obvious reason 
Leaks all of the time 
     
EQ-5D-5L utility score; mean (SD) [min – max]      
EQ5D visual analogue score; mean (SD) [min 
– max] 
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B-IPQ total score; mean (SD) [min – max]      




     
 
Table 17: Sensitivity analysis: comparison of results of primary analysis using the ITT population and analysis 
excluding those patients later found to be ineligible (IPSS Score at 12 months) 
 n Mean SD Min - Max Difference in 
meansa 
95% CI p-value 
Primary analysis of 
IPSS scores at 12 
months 
       
Primary analysis of 
IPSS scores at 12 
months excluding 
patients later 
found to be 
ineligible 
       
a Analysis adjusted for baseline IPSS score and minimisation variables 
 
 
Table 18: Sensitivity analysis: comparison of results of primary analysis with and without adjusting for the COVID- 
19 pandemic (IPSS score at 12 months) 
 n Mean SD Min - Max Difference in 
meansa 
95% CI p-value 
Primary analysis of 
IPSS scores at 12 
months 





       
a Analysis adjusted for baseline IPSS score and minimisation variables 
 
 
Table 19: Sensitivity analysis: comparison of results of ITT analysis of complete cases with ITT analysis where 
missing data were imputed for IPSS scores (12 months) 




95% CI p-value 
ITT        
Best case scenario        
Worst case scenario        
MICE        
a Analysis adjusted for baseline IPSS score and minimisation variables 
 
Table 20: Sensitivity analysis: comparison of results of primary analysis with and without the exclusion of outlier 
values (IPSS score 12 months) 
 n Mean SD Min - Max Difference in 
meansa 
95% CI p-value 
Primary analysis of 
IPSS scores at 12 
months including 
outlier values 
       
Primary analysis of 
IPSS scores at 12 
months excluding 
outlier values 
       
a Analysis adjusted for baseline IPSS score and minimisation variables 
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Table 21: Secondary outcome: mean and difference in mean patient-reported urinary symptom (IPSS) score at 6 months 
 n Mean SD Min - Max Difference 
in meansa 
95% CI p-value Difference 
in meansb 




95% CI p- 
value 
Intervention              
Usual care     
Total N     
ICC (95% CI)    
a ITT analysis adjusted for baseline IPSS score and randomisation variables 
b ITT analysis additionally adjusted for variables that show an imbalance between treatment groups at baseline 
c ITT analysis adjusted for baseline IPSS score 
 
 
Table 22: Mean and difference in mean patient-reported urinary symptom (IPSS) score using repeated measures data at 6 and 12 months 




95% CI p-value Difference in 
meansb 
95% CI p-value Difference in 
meansc 
95% CI p-value 
Intervention              
Usual care     
Total N     
ICC (95% CI)      
a ITT analysis adjusted for baseline IPSS score and minimisation variables 
b ITT analysis additionally adjusted for variables that show an imbalance between treatment groups at baseline 
c ITT analysis adjusted for baseline IPSS score 
 
 
Table 23: Secondary outcome: mean and difference in mean patient-reported urinary symptom (ICIQ-UI-SF) score at 6 and 12 months 




95% CI p-value Difference in 
meansb 
95% CI p-value Difference in 
meansc 
95% CI p-value 
6 months 
Intervention              
Usual care     
Total N     
ICC (95% CI)    
12 months 
Intervention              
Usual care     
Total N     
ICC (95% CI)    
a ITT analysis adjusted for baseline ICIQ-UI-SF score and minimisation variables 
b ITT analysis additionally adjusted for variables that show an imbalance between treatment groups at baseline 
c ITT analysis adjusted for baseline ICIQ-UI-SF score 
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Table 24: Secondary outcome: mean and difference in mean LUTS specific quality of life (IPSS QoL) at 6 and 12 months 




95% CI p-value Difference in 
meansb 
95% CI p-value Difference in 
meansc 
95% CI p-value 
6 months 
Intervention              
Usual care     
Total N     
ICC (95% CI)    
12 months 
Intervention              
Usual care     
Total N     
ICC (95% CI)    
a ITT analysis adjusted for baseline IPSS QoL and minimisation variables 
b ITT analysis additionally adjusted for variables that show an imbalance between treatment groups at baseline 
c ITT analysis adjusted for baseline IPSS QoL score 
 
Table 25: Secondary outcome: mean and difference in mean score of patient perception of LUTS (B-IPQ) at 6 and 12 months 




95% CI p-value Difference in 
meansb 
95% CI p-value Difference in 
meansc 
95% CI p-value 
6 months 
Intervention              
Usual care     
Total N     
ICC (95% CI)    
12 months 
Intervention              
Usual care     
Total N     
ICC (95% CI)    
a ITT analysis adjusted for baseline B-IPQ score and randomisation variables 
b ITT analysis additionally adjusted for variables that show an imbalance between treatment groups at baseline 
c ITT analysis adjusted for baseline B-IPQ score 
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Table 26: Secondary outcome: percentage and OR of referral to secondary care (urology) 
 N n %a OR
b 95% CI p-value ORc 95% CI p-value ORd 95% CI p-value 
Intervention             
Usual care    
Total N    
ICC (95% CI)    
a number with referral (n) in relation to number in treatment arm (N) 
b ITT analysis adjusted for whether or not the patient had a referral pre-baseline and minimisation variables 
c ITT analysis additionally adjusted for variables that show an imbalance between treatment groups at baseline 
d ITT analysis adjusted for whether or not the patient had a referral pre-baseline 
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Figure 4 Relationship between EQ-5D-5L and IPSS-QoL at baseline 




9.4 Safety data: Summary tables and listings of all adverse events and serious adverse events 













Table 28: All adverse events including severity classification 
 Received Intervention Received Usual care 
Adverse events 
Total number of SAEs; n   
Total number of related AEs; n   
Total number of deaths; n   
Status of SAEs; n(%)a   
Recovered   
Recovered with sequelae   
Still present   
a Denominator for the proportion is the total number of SAEs 
 
Table 29: All related adverse events by patient 
 Received Intervention Received Usual care 
Related adverse events; n(%) 
No adverse events   
1 adverse event   
More than 1 adverse event   
 
Table 30: List of individual SAEs 
 
Centre Practice Received 
intervention 






Description Outcome Related to 
intervention? 
…        
 Received Intervention Received Usual care 
Total number of events 
LUTS-related hospital admission; n   
LUTS-related urinary tract infection; n   
Urinary retention; n   
Prostatitis; n   
Number of patients having at least one 
event 
  
LUTS-related hospital admission; n(%)   
LUTS-related urinary tract infection; n(%)   
Urinary retention; n(%)   
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